Precision BioSciences Reports Third Quarter 2019 Financial Results and Highlights Ongoing Operational Progress Including Initial Data from PBCAR0191 Phase 1/2a Clinical Trial
12 nov. 2019 07h15 HE
|
Precision Biosciences
DURHAM, N.C., Nov. 12, 2019 (GLOBE NEWSWIRE) -- Precision BioSciences, Inc. (Nasdaq: DTIL) (“Precision”), a genome editing company dedicated to improving life through the application of its...
Yield10 Bioscience Signs Exclusive Worldwide License with University of Missouri for Advanced Technology Used to Boost Oil Content in Crops
08 mai 2019 08h30 HE
|
Yield10 Bioscience, Inc.
WOBURN, Mass., May 08, 2019 (GLOBE NEWSWIRE) -- Yield10 Bioscience, Inc. (Nasdaq:YTEN), an agricultural bioscience company which uses its “Trait Factory” to develop high value seed traits for the...
Yield10 Bioscience CEO Oliver Peoples to Present at the Advanced Bioeconomy Leadership Conference on April 3, 2019
02 avr. 2019 08h00 HE
|
Yield10 Bioscience, Inc.
WOBURN, Mass., April 02, 2019 (GLOBE NEWSWIRE) -- Yield10 Bioscience, Inc. (Nasdaq:YTEN), an agricultural bioscience company which uses its “Trait Factory” to develop high value seed traits for the...
Yield10 Bioscience Obtains Nonregulated Status for its Novel CRISPR-Cas9 Triple Gene Edited Camelina Plant Lines to Boost Seed Oil Content
02 oct. 2018 08h00 HE
|
Yield10 Bioscience, Inc.
--USDA-APHIS Response Marks Clearance of Yield10’s First Triple Genome-edited Plant Lines --Favorable Response Accelerates Path to U.S. Field Trials in 2019 WOBURN, Mass., Oct. 02, 2018 (GLOBE...
Yield10 Bioscience Signs Research License Agreement Covering CRISPR-Cas9 Genome-Editing Technology with the Broad Institute and Pioneer
08 août 2018 08h30 HE
|
Yield10 Bioscience, Inc.
WOBURN, Mass., Aug. 08, 2018 (GLOBE NEWSWIRE) -- Yield10 Bioscience, Inc. (Nasdaq:YTEN), a Company developing new technologies to create step-change improvements in crop yield to enhance global food...
Intellia Therapeutics Announces European Patent Office’s Decision to Grant CRISPR/Cas9 Genome Editing Technology Patent
11 avr. 2017 07h30 HE
|
Intellia Therapeutics, Inc.
Patent covers foundational CRISPR/Cas9 inventions that Intellia sublicensed for use in human therapeuticsPatent covers compositions of CRISPR single guide RNA technology for use in non-cellular and...